Ganciclovir-induced mutations are present in a diverse spectrum of post-transplant malignancies.

ABSTRACT:

Background

Ganciclovir (GCV) is widely used in solid organ and haematopoietic stem cell transplant patients for prophylaxis and treatment of cytomegalovirus. It has long been considered a mutagen and carcinogen. However, the contribution of GCV to cancer incidence and other factors that influence its mutagenicity remains unknown.

Methods

This retrospective cohort study analysed genomics data for 121,771 patients who had undergone targeted sequencing compiled by the Genomics Evidence Neoplasia Information Exchange (GENIE) or Foundation Medicine (FM). A statistical approach was developed to identify patients with GCV-associated mutational signature (GCV^sig) from targeted sequenced data of tumour samples. Cell line exposure models were further used to quantify mutati

SUBMITTER: Fang H 

PROVIDER: S-EPMC9620652 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature